NVCT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
31.0M
+331.4%
7.2M
+15.0%
6.3M
-17.8%
7.6M
-2.3%
7.8M
R&D
27.4M
+484.3%
4.7M
+14.1%
4.1M
-19.3%
5.1M
-11.9%
5.8M
SG&A
3.7M
+46.4%
2.5M
+16.7%
2.2M
-14.9%
2.5M
+25.3%
2.0M
Operating Income
-31049000
-331.4%
-7197000
-15.0%
-6260000
+17.8%
-7617000
+2.3%
-7794000
EBITDA
-31049000
-331.4%
-7197000
-15.0%
-6260000
+17.8%
-7617000
+2.3%
-7794000
Net Income
-30070000
-328.3%
-7020000
-16.0%
-6050000
+17.3%
-7314000
+2.0%
-7462000
EPS (Basic)
$-1.02
-240.0%
$-0.30
-15.4%
$-0.26
+16.1%
$-0.31
+29.5%
$-0.44
EPS (Diluted)
$-1.02
-240.0%
$-0.30
-15.4%
$-0.26
+16.1%
$-0.31
+29.5%
$-0.44
Shares (Diluted)
29.5M
+25.5%
23.5M
+0.3%
23.4M
+0.8%
23.2M
+2.2%
22.7M
Nuvectis Pharma (NVCT) — Financials